Updates on Combination Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia

Purpose of Review Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with a large clinical burden and high rates of treatment failure with first-line treatment options. Literature for combination antimicrobial therapies for initial treatment or salvage therapy in the setting...

Full description

Saved in:
Bibliographic Details
Published in:Current infectious disease reports 2020-10, Vol.22 (10), Article 28
Main Authors: Blackman, Alison L., Rubin, Ellen C., Broadbent, Eleanor K., Brade, Karrine D.
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial Development and Drug Resistance (KC Claeys and J Smith
Combination therapy
Drug resistance
Endocarditis
Infectious Diseases
Medicine
Medicine & Public Health
Mortality
Penicillin
Section Editors
Staphylococcus infections
Topical Collection on Antimicrobial Development and Drug Resistance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with a large clinical burden and high rates of treatment failure with first-line treatment options. Literature for combination antimicrobial therapies for initial treatment or salvage therapy in the setting of persistent bacteremia is developing. Recent Findings Various combination strategies have emerged for the treatment of MRSA bacteremia, including vancomycin or daptomycin in combination with either anti-staphylococcal penicillins, early- and late-generation cephalosporins, ceftaroline, trimethoprim-sulfamethoxazole, or fosfomycin. When used as second-line or salvage therapy, evidence suggests use of these combinations shorten the duration of bacteremia. More recently, data have emerged evaluating this strategy for initial therapy, although results are conflicting. Summary Use of combination therapy for MRSA bacteremia may shorten bacteremia duration, but the optimal combination, doses, timing of use, and exact impact on clinical outcomes are still evolving.
ISSN:1523-3847
1534-3146
DOI:10.1007/s11908-020-00737-8